Learn more

NABI BIOPHARMACEUTICALS

Overview
  • Total Patents
    112
About

NABI BIOPHARMACEUTICALS has a total of 112 patent applications. Its first patent ever was published in 1994. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are IST FARMACOTERAPICO IT SPA, AUTOIMMUNE INC and LEES ANDREW.

Patent filings per year

Chart showing NABI BIOPHARMACEUTICALSs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Fattom Ali Ibrahim 40
#2 Ennifar Sofiane 28
#3 Naso Robert B 28
#4 Fattom Ali 25
#5 Fattom Ali I 23
#6 Taylor Kimberly L 15
#7 Winston Scott 13
#8 Fuller Steve 13
#9 Kessler Paul 13
#10 Fahim Raafat 13

Latest patents

Publication Filing date Title
US2011182918A1 Personalized drug treatment and smoking cessation kit and method
WO2011014679A1 Method and kit for treating nicotine addiction
CA2727617A1 Smoking cessation kit and method
US2007212364A1 Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP1963308A2 Method for making nicotine hapten
CA2611023A1 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
WO2006076058A1 Method of treating staphylococcus aureus infection
US2006228368A1 Method of protecting against staphylococcal infection
US2006134141A1 Glycoconjugate vaccines containing peptidoglycan
NZ531647A Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
KR20080089527A Glycoconjugate vaccines for use in immune-compromised populations
BR0212554A Method of protection of immunocompromised person, use of a glycoconjugate of a polysaccharide or glycopeptide bacterial surface antigen and an immunocarrier and kit
US2002131969A1 Compositions of β-glucans and specific antibodies
US6936258B1 Staphylococcus antigen and vaccine